VRCA Relative Valuation
VRCA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRCA is overvalued; if below, it's undervalued.
Historical Valuation
Verrica Pharmaceuticals Inc (VRCA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.42 is considered Undervalued compared with the five-year average of -4.46. The fair price of Verrica Pharmaceuticals Inc (VRCA) is between 2.88 to 3.78 according to relative valuation methord. Compared to the current price of 0.62 USD , Verrica Pharmaceuticals Inc is Undervalued By 78.33%.
Relative Value
Fair Zone
2.88-3.78
Current Price：0.62
78.33%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
-3.02
P/B
Median3y
19.62
Median5y
14.36
-94.90
FCF Yield
Median3y
-39.42
Median5y
-28.50
Competitors Valuation Multiple
The average P/S ratio for VRCA's competitors is 1.14, providing a benchmark for relative valuation. Verrica Pharmaceuticals Inc Corp (VRCA) exhibits a P/S ratio of 2.42, which is 113.09% above the industry average. Given its robust revenue growth of -10.12%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Verrica Pharmaceuticals Inc (VRCA) currently overvalued or undervalued?
What is Verrica Pharmaceuticals Inc (VRCA) fair value?
How does VRCA's valuation metrics compare to the industry average?
What is the current P/B ratio for Verrica Pharmaceuticals Inc (VRCA) as of Jun 16 2025?
What is the current FCF Yield for Verrica Pharmaceuticals Inc (VRCA) as of Jun 16 2025?
What is the current Forward P/E ratio for Verrica Pharmaceuticals Inc (VRCA) as of Jun 16 2025?